Elutia (ELUT) said Monday it has agreed to a national group purchasing contract for its EluPro antibiotic-eluting cardiac implant with Premier (PINC), allowing Premier members to take advantage of special pre-negotiated pricing for the heart rhythm management device.
Financial terms and other details of the new contract weren't disclosed.
EluPro was developed to deliver powerful antibiotics directly to the surgical site, helping promote healing and reducing inflammation and scarring by forming a vascularized pocket of the patient's tissue surrounding the implantable device, Elutia said.
Elutia shares recently were up nearly 4% in early trading Monday, while Premier's shares were down 0.7%.
Price: 4.30, Change: +0.16, Percent Change: +3.86
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.